Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for ASND.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 1.642B
March 31, 2026 562.24M
December 31, 2025 -191.23M
September 30, 2025 -204.54M
June 30, 2025 -220.18M
March 31, 2025 -205.03M
December 31, 2024 -109.46M
September 30, 2024 -108.61M
June 30, 2024 -344.17M
March 31, 2024 -257.23M
December 31, 2023 -160.94M
September 30, 2023 -77.75M
June 30, 2023 70.74M
March 31, 2023 181.66M
December 31, 2022 281.06M
September 30, 2022 442.36M
June 30, 2022 635.47M
March 31, 2022 748.61M
December 31, 2021 1.005B
September 30, 2021 1.151B
June 30, 2021 815.29M
March 31, 2021 943.55M
December 31, 2020 1.026B
September 30, 2020 1.116B
June 30, 2020 535.90M
Date Value
March 31, 2020 602.21M
December 31, 2019 670.26M
September 30, 2019 720.54M
June 30, 2019 768.78M
March 31, 2019 804.70M
December 31, 2018 320.14M
September 30, 2018 353.33M
June 30, 2018 387.89M
March 31, 2018 427.27M
December 31, 2017 224.80M
September 30, 2017 238.98M
June 30, 2017 144.24M
March 31, 2017 165.60M
December 31, 2016 186.28M
September 30, 2016 83.61M
June 30, 2016 101.00M
March 31, 2016 116.13M
December 31, 2015 130.71M
September 30, 2015 147.03M
June 30, 2015 151.23M
March 31, 2015
December 31, 2014 55.43M
September 30, 2014 3.157M
June 30, 2014 5.664M
March 31, 2014

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Evaxion AS 9.531M
Genmab A/S 5.957B
Zealand Pharma A/S 2.753B
Cellectis SA 41.07M
BioMarin Pharmaceutical, Inc. 6.322B

Shareholders Equity (Quarterly) Related Metrics